Safe Orthopaedics closes 2019 with its best quarterly performance

1 502 K€, an increase of 52%

Regulatory News:

Safe Orthopaedics (Paris:ALSAF) (FR0012452746 – ALSAF), a company specializing in the design and marketing of single-use implants and instruments for the minimally invasive treatment of spinal fracture conditions, is today announcing its 2019 fourth quarter turnover, 2019 annual turnover and cash position.

In thousands of euros

2019

(12 months)

2018

(12 months)

Variation

Direct sales (FR, Ger, UK)

2 024

2 134

-5%

Indirect sales

2 677

1 337

+102%

Total revenues

4 702

3 471

+35%

In 2019, Safe Orthopaedics turnover was 4 702 K€, an increase of +35% compared to the year 2018, driven by indirect sales forces and mainly the Japanese partnership. The reduction of annual direct sales by 5% is only recognized on French market. The management had announced in September 27th, 2019, a restructuration and reinforcement of sales and marketing forces, in order to reinvigorate the sales by means of a different commercial approach and the renewal of SteriSpine PS range.

In thousands of euros	Q1 2019 (3 months)	Q2 2019 (3 months)	Q3 2019 (3 months)	Q4 2019 (3 months)
Direct sales (FR, Ger, UK)	551 (+6%)	458 (-2%)	483 (-7%)	532 (-16%)
Indirect sales	527 (+32%)	506 (+90%)	675 (+123%)	969 (+171%)
Total revenues	1 078 (+16%)	964 (+32%)	1 158 (+41%)